The Medical Management of Cerebral Edema: Past, Present, and Future Therapies

Michael R. Halstead, Romergryko G. Geocadin

Research output: Contribution to journalArticle

Abstract

Cerebral edema is commonly associated with cerebral pathology, and the clinical manifestation is largely related to the underlying lesioned tissue. Brain edema usually amplifies the dysfunction of the lesioned tissue and the burden of cerebral edema correlates with increased morbidity and mortality across diseases. Our modern-day approach to the medical management of cerebral edema has largely revolved around, an increasingly artificial distinction between cytotoxic and vasogenic cerebral edema. These nontargeted interventions such as hyperosmolar agents and sedation have been the mainstay in clinical practice and offer noneloquent solutions to a dire problem. Our current understanding of the underlying molecular mechanisms driving cerebral edema is becoming much more advanced, with differences being identified across diseases and populations. As our understanding of the underlying molecular mechanisms in neuronal injury continues to expand, so too is the list of targeted therapies in the pipeline. Here we present a brief review of the molecular mechanisms driving cerebral edema and a current overview of our understanding of the molecular targets being investigated.

Original languageEnglish (US)
JournalNeurotherapeutics
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Brain Edema
Therapeutics
Clinical Pathology
Morbidity
Mortality
Wounds and Injuries
Population

Keywords

  • Cerebral edema
  • cytotoxic edema
  • elevated ICP
  • hyperosmolar therapy
  • vasogenic edema

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

The Medical Management of Cerebral Edema : Past, Present, and Future Therapies. / Halstead, Michael R.; Geocadin, Romergryko G.

In: Neurotherapeutics, 01.01.2019.

Research output: Contribution to journalArticle

@article{81c8bf9857854e2497275649b71c07cf,
title = "The Medical Management of Cerebral Edema: Past, Present, and Future Therapies",
abstract = "Cerebral edema is commonly associated with cerebral pathology, and the clinical manifestation is largely related to the underlying lesioned tissue. Brain edema usually amplifies the dysfunction of the lesioned tissue and the burden of cerebral edema correlates with increased morbidity and mortality across diseases. Our modern-day approach to the medical management of cerebral edema has largely revolved around, an increasingly artificial distinction between cytotoxic and vasogenic cerebral edema. These nontargeted interventions such as hyperosmolar agents and sedation have been the mainstay in clinical practice and offer noneloquent solutions to a dire problem. Our current understanding of the underlying molecular mechanisms driving cerebral edema is becoming much more advanced, with differences being identified across diseases and populations. As our understanding of the underlying molecular mechanisms in neuronal injury continues to expand, so too is the list of targeted therapies in the pipeline. Here we present a brief review of the molecular mechanisms driving cerebral edema and a current overview of our understanding of the molecular targets being investigated.",
keywords = "Cerebral edema, cytotoxic edema, elevated ICP, hyperosmolar therapy, vasogenic edema",
author = "Halstead, {Michael R.} and Geocadin, {Romergryko G.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s13311-019-00779-4",
language = "English (US)",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",

}

TY - JOUR

T1 - The Medical Management of Cerebral Edema

T2 - Past, Present, and Future Therapies

AU - Halstead, Michael R.

AU - Geocadin, Romergryko G.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cerebral edema is commonly associated with cerebral pathology, and the clinical manifestation is largely related to the underlying lesioned tissue. Brain edema usually amplifies the dysfunction of the lesioned tissue and the burden of cerebral edema correlates with increased morbidity and mortality across diseases. Our modern-day approach to the medical management of cerebral edema has largely revolved around, an increasingly artificial distinction between cytotoxic and vasogenic cerebral edema. These nontargeted interventions such as hyperosmolar agents and sedation have been the mainstay in clinical practice and offer noneloquent solutions to a dire problem. Our current understanding of the underlying molecular mechanisms driving cerebral edema is becoming much more advanced, with differences being identified across diseases and populations. As our understanding of the underlying molecular mechanisms in neuronal injury continues to expand, so too is the list of targeted therapies in the pipeline. Here we present a brief review of the molecular mechanisms driving cerebral edema and a current overview of our understanding of the molecular targets being investigated.

AB - Cerebral edema is commonly associated with cerebral pathology, and the clinical manifestation is largely related to the underlying lesioned tissue. Brain edema usually amplifies the dysfunction of the lesioned tissue and the burden of cerebral edema correlates with increased morbidity and mortality across diseases. Our modern-day approach to the medical management of cerebral edema has largely revolved around, an increasingly artificial distinction between cytotoxic and vasogenic cerebral edema. These nontargeted interventions such as hyperosmolar agents and sedation have been the mainstay in clinical practice and offer noneloquent solutions to a dire problem. Our current understanding of the underlying molecular mechanisms driving cerebral edema is becoming much more advanced, with differences being identified across diseases and populations. As our understanding of the underlying molecular mechanisms in neuronal injury continues to expand, so too is the list of targeted therapies in the pipeline. Here we present a brief review of the molecular mechanisms driving cerebral edema and a current overview of our understanding of the molecular targets being investigated.

KW - Cerebral edema

KW - cytotoxic edema

KW - elevated ICP

KW - hyperosmolar therapy

KW - vasogenic edema

UR - http://www.scopus.com/inward/record.url?scp=85073987401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073987401&partnerID=8YFLogxK

U2 - 10.1007/s13311-019-00779-4

DO - 10.1007/s13311-019-00779-4

M3 - Article

C2 - 31512062

AN - SCOPUS:85073987401

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

ER -